Overview

A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma

Status:
Not yet recruiting

Trial end date:
2024-04-01

Target enrollment:

Participant gender:

Summary

This is a randomized, open-label, multicenter Phase Ib study to evaluate the effectiveness and safety of different doses of IBI310, bevacizumab combined with sintilimab in patients with locally advanced or metastatic HCC who have not previously received systemic therapy, are unsuitable for radical surgical resection or local treatment, or have progressive disease after surgical resection or local treatment.

Phase:

Phase 1

Details

Lead Sponsor:

Shanghai Zhongshan Hospital

Treatments:

Bevacizumab